|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gu B, Shang X, Yan M, Li X, Wang W, Wang Q
and Zhang C: Variations in incidence and mortality rates of
endometrial cancer at the global, regional, and national levels,
1990–2019. Gynecol Oncol. 161:573–580. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Cancer Society, . Endometrial
cancer survival rates, by stage. https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html
|
|
4
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N, et al: Cancer statistics in China and
United States, 2022: Profiles, trends, and determinants. Chin Med J
(Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al: ESMO-ESGO-ESTRO Endometrial Consensus Conference Working
Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer:
Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Musacchio L, Boccia SM, Caruso G,
Santangelo G, Fischetti M, Tomao F, Perniola G, Palaia I, Muzii L,
Pignata S, et al: Immune checkpoint inhibitors: A promising choice
for endometrial cancer patients? J Clin Med. 9:17212020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Cancer Institute, . Endometrial
cancer treatment Physician Data Query (PDQ). 2021.Available online.
http://www.cancer.gov/cancertopics/pdq/treatment/endometrial/healthprofessional13–August.
2021
|
|
8
|
NCCN Clinical Practice Guidelines in
Oncology, . Available online. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf13–August.
2020
|
|
9
|
Miller DS, Blessing JA, Lentz SS and
Waggoner SE: A phase II trial of topotecan in patients with
advanced, persistent, or recurrent endometrial carcinoma: A
gynecologic oncology group study. Gynecol Oncol. 87:247–251. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fracasso PM, Blessing JA, Molpus KL, Adler
LM, Sorosky JI and Rose PG: Phase II study of oxaliplatin as
second-line chemotherapy in endometrial carcinoma: A Gynecologic
Oncology Group study. Gynecol Oncol. 103:523–526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garcia AA, Blessing JA, Nolte S and Mannel
RS; Gynecologic Oncology Group, : A phase II evaluation of weekly
docetaxel in the treatment of recurrent or persistent endometrial
carcinoma: A study by the Gynecologic Oncology Group. Gynecol
Oncol. 111:22–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dizon DS, Blessing JA, McMeekin DS, Sharma
SK, Disilvestro P and Alvarez RD: Phase II trial of ixabepilone as
second-line treatment in advanced endometrial cancer: Gynecologic
oncology group trial 129-P. J Clin Oncol. 27:3104–3108. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Smith RA, von Eschenbach AC, Wender R,
Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C,
Runowicz C, et al: American Cancer Society guidelines for the early
detection of cancer: Update of early detection guidelines for
prostate, colorectal, and endometrial cancers. Also: Update
2001-testing for early lung cancer detection. CA Cancer J Clin.
51:38–75; quiz 77–80. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Raglan O, Kalliala I, Markozannes G,
Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E,
Martin-Hirsch P, Tsilidis KK, et al: Risk factors for endometrial
cancer: An umbrella review of the literature. Int J Cancer.
145:1719–1730. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu QJ, Li YY, Tu C, Zhu J, Qian KQ, Feng
TB, Li C, Wu L and Ma XX: Parity and endometrial cancer risk: A
meta-analysis of epidemiological studies. Sci Rep. 5:142432015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dunneram Y, Greenwood DC and Cade JE:
Diet, menopause and the risk of ovarian, endometrial and breast
cancer. Proc Nutr Soc. 78:438–448. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lauby-Secretan B, Scoccianti C, Loomis D,
Grosse Y, Bianchini F and Straif K; International Agency for
Research on Cancer Handbook Working Group, : Body fatness and
cancer-viewpoint of the IARC working group. N Engl J Med.
375:794–798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Painter JN, O'Mara TA, Marquart L, Webb
PM, Attia J, Medland SE, Cheng T, Dennis J, Holliday EG, McEvoy M,
et al: Genetic risk score mendelian randomization shows that
obesity measured as body mass index, but not waist: Hip ratio, is
causal for endometrial cancer. Cancer Epidemiol Biomarkers Prev.
25:1503–1510. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nead KT, Sharp SJ, Thompson DJ, Painter
JN, Savage DB, Semple RK, Barker A; Australian National Endometrial
Cancer Study Group (ANECS), ; Perry JR, Attia J, et al: Evidence of
a causal association between insulinemia and endometrial cancer: A
mendelian randomization analysis. J Natl Cancer Inst.
107:djv1782015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marlson MJ, Thiel KW, Yang S and Leslie
KK: Catch it before it kills: Progesterone, obesity, and the
prevention of endometrial cancer. Discov Med. 14:215–222.
2012.PubMed/NCBI
|
|
21
|
Khandekar MJ, Cohen P and Spiegelman BM:
Molecular mechanisms of cancer development in obesity. Nat Rev
Cancer. 11:886–895. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsilidis KK, Kasimis JC, Lopez DS, Ntzani
EE and Ioannidis JP: Type 2 diabetes and cancer: umbrella review of
meta-analyses of observational studies. BMJ. 350:g76072015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Buchanan EM, Weinstein LC and Hillson C:
Endometrial cancer. Am Fam Physician. 80:1075–1080. 2009.PubMed/NCBI
|
|
24
|
Parazzini F, La Vecchia C, Moroni S,
Chatenoud L and Ricci E: Family history and the risk of endometrial
cancer. Int J Cancer. 59:460–462. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aarnio M, Mecklin JP, Aaltonen LA,
Nyström-Lahti M and Järvinen HJ: Life-time risk of different
cancers in hereditary non-polyposis colorectal cancer (HNPCC)
syndrome. Int J Cancer. 64:430–433. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Obermair A, Youlden DR, Young JP, Lindor
NM, Baron JA, Newcomb P, Parry S, Hopper JL, Haile R and Jenkins
MA: Risk of endometrial cancer for women diagnosed with
HNPCC-related colorectal carcinoma. Int J Cancer. 127:2678–2684.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pilarski R, Burt R, Kohlman W, Pho L,
Shannon KM and Swisher E: Cowden syndrome and the PTEN hamartoma
tumor syndrome: Systematic review and revised diagnostic criteria.
J Natl Cancer Inst. 105:1607–1616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang
N, Zhu H and Wang B: Cigarette smoking and the risk of endometrial
cancer: A meta-analysis. Am J Med. 121:501–508.e3. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Loerbroks A, Schouten LJ, Goldbohm RA and
van den Brandt PA: Alcohol consumption, cigarette smoking, and
endometrial cancer risk: Results from the Netherlands Cohort Study.
Cancer Causes Control. 18:551–560. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lindemann K, Vatten LJ, Ellstrøm-Engh M
and Eskild A: Body mass, diabetes and smoking, and endometrial
cancer risk: A follow-up study. Br J Cancer. 98:1582–1585. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Michnovicz JJ, Hershcopf RJ, Naganuma H,
Bradlow HL and Fishman J: Increased 2-hydroxylation of estradiol as
a possible mechanism for the anti-estrogenic effect of cigarette
smoking. N Engl J Med. 315:1305–1309. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aune D, Navarro Rosenblatt DA, Chan DS,
Vingeliene S, Abar L, Vieira AR, Greenwood DC, Bandera EV and Norat
T: Anthropometric factors and endometrial cancer risk: A systematic
review and dose-response meta-analysis of prospective studies. Ann
Oncol. 26:1635–1648. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wilczyński M, Danielska J and Wilczyński
J: An update of the classical Bokhman's dualistic model of
endometrial cancer. Prz Menopauzalny. 15:63–68. 2016.PubMed/NCBI
|
|
35
|
Kandoth C, Schultz N, Cherniack AD, Akbani
R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al:
Integrated genomic characterization of endometrial carcinoma.
Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Piulats JM, Guerra E, Gil-Martín M,
Roman-Canal B, Gatius S, Sanz-Pamplona R, Velasco A, Vidal A and
Matias-Guiu X: Molecular approaches for classifying endometrial
carcinoma. Gynecol Oncol. 145:200–207. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oaknin A, León-Castillo A and Lorusso D:
Progress in the management of endometrial cancer (subtypes,
immunotherapy, alterations in PIK3CA pathway): Data and
perspectives. Curr Opin Oncol. 32:471–480. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Talhouk A, McConechy MK, Leung S, Li-Chang
HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, et al:
A clinically applicable molecular-based classification for
endometrial cancers. Br J Cancer. 113:299–310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mamalis A, Garcha M and Jagdeo J:
Targeting the PD-1 pathway: A promising future for the treatment of
melanoma. Arch Dermatol Res. 306:511–519. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu Y, Chen W, Xu ZP and Gu W: PD-L1
Distribution and perspective for cancer immunotherapy-blockade,
knockdown, or inhibition. Front Immunol. 10:20222019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Alsaab HO, Sau S, Alzhrani R, Tatiparti K,
Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling
inhibition for cancer immunotherapy: Mechanism, combinations, and
clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Post CCB, Westermann AM, Bosse T,
Creutzberg CL and Kroep JR: PARP and PD-1/PD-L1 checkpoint
inhibition in recurrent or metastatic endometrial cancer. Crit Rev
Oncol Hematol. 152:1029732020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mo Z, Liu J, Zhang Q, Chen Z, Mei J, Liu
L, Yang S, Li H, Zhou L and You Z: Expression of PD-1, PD-L1 and
PD-L2 is associated with differentiation status and histological
type of endometrial cancer. Oncol Lett. 12:944–950. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
McMeekin DS, Tritchler DL, Cohn DE, Mutch
DG, Lankes HA, Geller MA, Powell MA, Backes FJ, Landrum LM, Zaino
R, et al: Clinicopathologic significance of mismatch repair defects
in endometrial cancer: An NRG Oncology/Gynecologic oncology group
study. J Clin Oncol. 34:3062–3068. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kautto EA, Bonneville R, Miya J, Yu L,
Krook MA, Reeser JW and Roychowdhury S: Performance evaluation for
rapid detection of pan-cancer microsatellite instability with
MANTIS. Oncotarget. 8:7452–7463. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Eggink FA, Van Gool IC, Leary A, Pollock
PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L,
Church DN, et al: Immunological profiling of molecularly classified
high-risk endometrial cancers identifies POLE-mutant and
microsatellite unstable carcinomas as candidates for checkpoint
inhibition. Oncoimmunology. 6:e12645652016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yamashita H, Nakayama K, Ishikawa M,
Nakamura K, Ishibashi T, Sanuki K, Ono R, Sasamori H, Minamoto T,
Iida K, et al: Microsatellite instability is a biomarker for immune
checkpoint inhibitors in endometrial cancer. Oncotarget.
9:5652–5664. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Piulats JM and Matias-Guiu X:
Immunotherapy in endometrial cancer: In the nick of time. Clin
Cancer Res. 22:5623–5625. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Miller DS, Filiaci VL, Mannel RS, Cohn DE,
Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell
MA, et al: Carboplatin and paclitaxel for advanced endometrial
cancer: Final overall survival and adverse event analysis of a
phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 38:3841–3850.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nomura H, Aoki D, Takahashi F, Katsumata
N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M and Yaegashi N:
Randomized phase II study comparing docetaxel plus cisplatin,
docetaxel plus carboplatin, and paclitaxel plus carboplatin in
patients with advanced or recurrent endometrial carcinoma: A
Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol.
22:636–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
McMeekin S, Dizon D, Barter J, Scambia G,
Manzyuk L, Lisyanskaya A, Oaknin A, Ringuette S, Mukhopadhyay P,
Rosenberg J, et al: Phase III randomized trial of second-line
ixabepilone versus paclitaxel or doxorubicin in women with advanced
endometrial cancer. Gynecol Oncol. 138:18–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mehnert JM, Panda A, Zhong H, Hirshfield
K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L,
Kaufman HL, et al: Immune activation and response to pembrolizumab
in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ott PA, Bang YJ, Berton-Rigaud D, Elez E,
Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, et
al: Safety and antitumor activity of pembrolizumab in advanced
programmed death ligand 1-positive endometrial cancer: Results From
the KEYNOTE-028 study. J Clin Oncol. 35:2535–2541. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite Instability/Mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Santin AD, Bellone S, Buza N, Choi J,
Schwartz PE, Schlessinger J and Lifton RP: Regression of
chemotherapy-resistant polymerase ε (POLE) Ultra-mutated and MSH6
Hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res.
22:5682–5687. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tamura K, Hasegawa K, Katsumata N,
Matsumoto K, Mukai H, Takahashi S, Nomura H and Minami H: Efficacy
and safety of nivolumab in Japanese patients with uterine cervical
cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter,
open-label phase 2 trial. Cancer Sci. 110:2894–2904. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kasherman L, Ahrari S and Lheureux S:
Dostarlimab in the treatment of recurrent or primary advanced
endometrial cancer. Future Oncol. 17:877–892. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Oaknin A, Tinker AV, Gilbert L, Samouëlian
V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A,
Abdeddaim C, et al: Clinical activity and safety of the
anti-programmed Death 1 monoclonal antibody dostarlimab for
patients with recurrent or advanced mismatch repair-deficient
endometrial cancer: A nonrandomized phase 1 clinical Trial. JAMA
Oncol. 6:1766–1772. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liu JF, Gordon M, Veneris J, Braiteh F,
Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, et
al: Safety, clinical activity and biomarker assessments of
atezolizumab from a Phase I study in advanced/recurrent ovarian and
uterine cancers. Gynecol Oncol. 154:314–322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Konstantinopoulos PA, Luo W, Liu JF,
Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB,
Crowe H, et al: Phase II Study of Avelumab in patients with
mismatch repair deficient and mismatch repair proficient
recurrent/persistent endometrial cancer. J Clin Oncol.
37:2786–2794. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Antill Y, Kok PS, Robledo K, Yip S,
Cummins M, Smith D, Spurdle A, Barnes E, Lee YC, Friedlander M, et
al: Clinical activity of durvalumab for patients with advanced
mismatch repair-deficient and repair-proficient endometrial cancer.
A nonrandomized phase 2 clinical trial. J Immunother Cancer.
9:e0022552021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Mittica G, Ghisoni E, Giannone G, Aglietta
M, Genta S and Valabrega G: Checkpoint inhibitors in endometrial
cancer: Preclinical rationale and clinical activity. Oncotarget.
8:90532–90544. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kato Y, Tabata K, Kimura T,
Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y,
Matsuki M, et al: Lenvatinib plus anti-PD-1 antibody combination
treatment activates CD8+ T cells through reduction of
tumor-associated macrophage and activation of the interferon
pathway. PLoS One. 14:e02125132019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Taylor MH, Lee CH, Makker V, Rasco D,
Dutcus CE, Wu J, Stepan DE, Shumaker RC and Motzer RJ: Phase IB/II
trial of Lenvatinib plus pembrolizumab in patients with advanced
renal cell carcinoma, endometrial cancer, and other selected
advanced solid tumors. J Clin Oncol. 38:1154–1163. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Makker V, Rasco D, Vogelzang NJ, Brose MS,
Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, et
al: Lenvatinib plus pembrolizumab in patients with advanced
endometrial cancer: An interim analysis of a multicentre,
open-label, single-arm, phase 2 trial. Lancet Oncol. 20:711–718.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Makker V, Taylor MH, Aghajanian C, Oaknin
A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, et al:
Lenvatinib plus pembrolizumab in patients with advanced endometrial
cancer. J Clin Oncol. 38:2981–2992. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lheureux S, Matei D, Konstantinopoulos PA,
Block MS, Jewell A, Gaillard S, McHale MS, McCourt CK, Temkin S,
Girda E, et al: A randomized phase II study of cabozantinib and
nivolumab versus nivolumab in recurrent endometrial cancer. J Clin
Oncol. 38:60102020. View Article : Google Scholar
|
|
73
|
Rousset-Rouviere S, Rochigneux P, Chrétien
AS, Fattori S, Gorvel L, Provansal M, Lambaudie E, Olive D and
Sabatier R: Endometrial carcinoma: Immune microenvironment and
emerging treatments in immuno-oncology. Biomedicines. 9:6322021.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Fumet JD, Limagne E, Thibaudin M, Truntzer
C, Bertaut A, Rederstorff E and Ghiringhelli F: Precision medicine
phase II study evaluating the efficacy of a double immunotherapy by
durvalumab and tremelimumab combined with olaparib in patients with
solid cancers and carriers of homologous recombination repair genes
mutation in response or stable after olaparib treatment. BMC
Cancer. 20:7482020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Green AK, Feinberg J and Makker V: A
review of immune checkpoint blockade therapy in endometrial cancer.
Am Soc Clin Oncol Educ Book. 40:1–7. 2020.PubMed/NCBI
|
|
76
|
Zitvogel L, Kepp O and Kroemer G: Immune
parameters affecting the efficacy of chemotherapeutic regimens. Nat
Rev Clin Oncol. 8:151–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Liu WM, Fowler DW, Smith P and Dalgleish
AG: Pre-treatment with chemotherapy can enhance the antigenicity
and immunogenicity of tumours by promoting adaptive immune
responses. Br J Cancer. 102:115–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Luke JJ, Lemons JM, Karrison TG, Pitroda
SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch
L, et al: Safety and clinical activity of pembrolizumab and
multisite stereotactic body radiotherapy in patients with advanced
solid tumors. J Clin Oncol. 36:1611–1618. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Walle T, Martinez Monge R, Cerwenka A,
Ajona D, Melero I and Lecanda F: Radiation effects on antitumor
immune responses: Current perspectives and challenges. Ther Adv Med
Oncol. 10:17588340177425752018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Lee L and Matulonis U: Immunotherapy and
radiation combinatorial trials in gynecologic cancer: A potential
synergy? Gynecol Oncol. 154:236–245. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Tuyaerts S, Van Nuffel AMT, Naert E, Van
Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L,
De Jaeghere E, et al: PRIMMO study protocol: A phase II study
combining PD-1 blockade, radiation and immunomodulation to tackle
cervical and uterine cancer. BMC Cancer. 19:5062019. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Grandin M, Meier M, Delcros JG, Nikodemus
D, Reuten R, Patel TR, Goldschneider D, Orriss G, Krahn N,
Boussouar A, et al: Structural decoding of the Netrin-1/UNC5
interaction and its therapeutical implications in cancers. Cancer
Cell. 29:173–185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Paradisi A, Creveaux M, Gibert B, Devailly
G, Redoulez E, Neves D, Cleyssac E, Treilleux I, Klein C,
Niederfellner G, et al: Combining chemotherapeutic agents and
netrin-1 interference potentiates cancer cell death. EMBO Mol Med.
5:1821–1834. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Pakish JB and Jazaeri AA: Immunotherapy in
gynecologic cancers: Are We there yet? Curr Treat Options Oncol.
18:592017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pakish JB, Zhang Q, Chen Z, Liang H,
Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH and Yates MS:
Immune microenvironment in microsatellite-instable endometrial
cancers: Hereditary or sporadic origin matters. Clin Cancer Res.
23:4473–4481. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tronconi F, Nero C, Giudice E, Salutari V,
Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F,
et al: Advanced and recurrent endometrial cancer: State of the art
and future perspectives. Crit Rev Oncol Hematol. 180:1038512022.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Abu-Rustum N, Yashar C, Arend R, Barber E,
Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Chu C, et al:
Uterine Neoplasms, Version 1.2023, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 21:181–209. 2023.
View Article : Google Scholar : PubMed/NCBI
|
